National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone. HTA ID: 21041

Daratumumab (Darzalex®) is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain amyloidosis.

 

NCPE Assessment Process Complete
Rapid review commissioned 03/09/2021
Rapid review completed 13/10/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of daratumumab compared with the current standard of care.